AUPH — Aurinia Pharmaceuticals Inc
NASDAQ · Healthcare · Biotechnology
$16.06
+$0.01 (+0.06%)
Aurinia Pharmaceuticals Inc (AUPH) is a biotechnology company listed on NASDAQ. It is led by Peter S. Greenleaf M.B.A., based in #140, 14315 ? 118 Avenue, Edmonton, AB, Canada, T5L 4S6, with about 130 employees. Aurinia Pharmaceuticals Inc. is a biopharmaceutical company that engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs. It offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. The company also develops AUR200, a dual inhibitor of B cell activating factor and a proliferation inducing ligand for the potential treatment of autoimmune diseases. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
Latest reported AUPH revenue for 2025-09-30 was $73.5M. Net income was $31.6M. Revenue was up 4.9% from 2025-06-30 to 2025-09-30. AUPH currently screens at market cap $1.03B and trailing P/E 28.1.
Use this AUPH page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the AUPH quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the AUPH SEC filings page. Lician reads the product cache first so this HTML stays unique to Aurinia Pharmaceuticals Inc even when a live quote feed is slow.
About Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company that engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs. It offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. The company also develops AUR200, a dual inhibitor of B cell activating factor and a proliferation inducing ligand for the potential treatment of autoimmune diseases. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
AUPH Key Statistics
Market Cap
$1.03B
Volume
779,346
Previous Close
$16.57
Day Range
$16.54 – $16.83
P/E Ratio
28.11
EPS
$0.01
Revenue
$59.87M
Net Income
$1.43M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+32.8%
Profit Margin
2.4%
Employees
130
AUPH Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 |
|---|---|---|
| Revenue | $59.87M | $45.09M |
| Cost of Revenue | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 |
| Net Income | $1.43M | -$26.88M |
| EPS (Diluted) | $0.01 | -$0.19 |
Total Assets
$550.64M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$83.40M
Operating Cash Flow
$44.39M
Free Cash Flow
$0.00
Aurinia Pharmaceuticals Inc Company Information
- President, CEO & Director
- Peter S. Greenleaf M.B.A.
- Headquarters
- #140, 14315 ? 118 Avenue, Edmonton, AB, Canada, T5L 4S6
- Website
- www.auriniapharma.com
- Phone
- 250 744 2487
- IPO / Founded
- 1999-01-26
- Sector
- Healthcare
- Industry
- Biotechnology